Overview of Spravato (Esketamine) Costs in 2026
Spravato (esketamine) has established itself as a breakthrough, FDA-approved nasal spray treatment for treatment-resistant depression (TRD) and major depressive disorder (MDD) accompanied by acute suicidal ideation or behavior. However, for both prospective patients and clinic managers operating behavioral health practices, navigating the financial landscape of Spravato therapy remains complex.
Unlike conventional oral antidepressants picked up at a retail pharmacy, Spravato involves a two-part cost structure: the cost of the medication itself and the professional clinical service fee for mandatory in-office medical monitoring. Because esketamine is classified as a Schedule III controlled substance with potential side effects such as sedation, dissociation, and transient blood pressure spikes, the FDA requires administration under a Risk Evaluation and Mitigation Strategy (REMS) program.
In 2026, the overall cash price for a single Spravato session ranges between $600 and $1,500+, depending on the dosage, facility setting, and geographical location. However, out-of-pocket costs for insured patients are substantially lower—frequently dropping to $10 to $250 per session when leveraging manufacturer savings programs and standard health plan benefits.
Cost Per Dose and Full Treatment Course Breakdown
To understand total costs, it is essential to distinguish between the Wholesale Acquisition Cost (WAC) of the drug and the comprehensive bill for a complete treatment protocol.
[Total Session Cost] = [Medication WAC / Specialty Cost] + [Facility & REMS Observation Fee]
1. Per-Dose Medication Pricing
Spravato is packaged in single-use nasal spray devices containing 28 mg of esketamine per device:
- 56 mg Dose (Two 28 mg devices): The baseline Wholesale Acquisition Cost (WAC) is approximately $590 for the medication alone.
- 84 mg Dose (Three 28 mg devices): The maintenance WAC is approximately $885 for the medication alone.
Note: WAC represents the list price charged to wholesalers and distributors. Clinics and specialty pharmacies may mark up or negotiate these rates depending on their purchasing volume and payer contracts.
2. Treatment Course Progression
Spravato is administered in distinct clinical phases. Total treatment costs fluctuate based on protocol progression:
- Induction Phase (Weeks 1–4): Administered twice weekly (8 total sessions). Patients receive 56 mg for session one and typically titrate to 84 mg for sessions 2–8.
- Uninsured / Cash-Pay Total: $4,800 – $11,200
- Insured Out-of-Pocket Total: $80 – $1,600 (with copay assistance: as low as $80)
- Continuation Phase (Weeks 5–8): Administered once weekly (4 total sessions) at 84 mg.
- Uninsured / Cash-Pay Total: $2,400 – $5,600
- Insured Out-of-Pocket Total: $40 – $800
- Maintenance Phase (Week 9+): Administered every 1 to 2 weeks based on clinical symptom retention.
- Uninsured / Cash-Pay Monthly Cost: $1,200 – $2,800
- Insured Monthly Out-of-Pocket: $20 – $400
FDA REMS Program Requirements: Why Observation Adds Cost
The FDA REMS program dictates that Spravato must be administered under the direct supervision of a healthcare provider at a certified REMS medical facility. Patients are required to stay at the clinic for a minimum of two hours following self-administration to monitor for adverse hemodynamic or cognitive effects.
+-----------------------------------------------------------------------+
| REMS Session Workflow & Overhead |
+-----------------------------------------------------------------------+
| 1. Pre-Administration Assessment (Vitals, BP check, psychiatric fit) |
| 2. Self-Administration (Patient sprays esketamine under observation) |
| 3. 2-Hour Post-Dose Monitoring (Sedation, dissociation, BP checks) |
| 4. Post-Observation Discharge Clearance (Gait/sensorium verification)|
+-----------------------------------------------------------------------+
Clinic Overhead & Billing Mechanics
From an operational perspective, the 2-hour monitoring requirement creates real overhead costs for clinics, including dedicated quiet rooms or recliner bays, continuous clinical staff presence (RNs, MA-monitors, or APPs), and blood pressure monitoring technology.
Clinics bill these combined services using specific Healthcare Common Procedure Coding System (HCPCS) codes:
- G2082: Supervised provision of esketamine, nasal spray, 56 mg or less, including 2 hours of post-administration observation.
- G2083: Supervised provision of esketamine, nasal spray, greater than 56 mg (84 mg), including 2 hours of post-administration observation.
- J0013: Esketamine, nasal spray, 1 mg (used when medication is sourced via specialty pharmacy under a pharmacy benefit model).
Insurance Coverage: Commercial, Medicare, and Medicaid
Insurance coverage for Spravato has broadened significantly, though prior authorization (PA) criteria remain rigorous.
Commercial Insurance
Most major national carriers (such as UnitedHealthcare, Anthem/Elevance, Aetna, Cigna, and Humana) cover Spravato under either the medical benefit (“buy-and-bill”) or pharmacy benefit.
- Prior Authorization Criteria: Patients generally must meet diagnostic criteria for TRD (failing 2 to 4 classes of oral antidepressants during the current depressive episode) and remain on a concurrent oral antidepressant.
- Cost-Sharing: Insured patients typically face standard specialist copays ($30–$75/session) or coinsurance (10%–30% after deductible).
Medicare Coverage
- Medicare Part B (Medical Benefit): When billed by a clinic under the “buy-and-bill” model using HCPCS codes G2082 and G2083, Medicare Part B covers 80% of the Medicare-approved amount after the annual Part B deductible ($240–$257 range). A Supplemental Policy (Medigap) or secondary insurance usually picks up the remaining 20% coinsurance, bringing out-of-pocket costs close to $0.
- Medicare Part D (Pharmacy Benefit): If the clinic uses a specialty pharmacy, medication falls under Part D. Under the Inflation Reduction Act provisions in effect for 2026, total annual out-of-pocket prescription drug spending under Part D is capped at $2,000, offering substantial relief for high-cost biologic and specialty medications.
Medicaid Coverage
Medicaid coverage for Spravato is managed on a state-by-state basis:
- Fee-for-Service & Managed Medicaid: The vast majority of state Medicaid programs list Spravato on their formularies, though prior authorization requirements are strictly enforced.
- Patient Out-of-Pocket: For covered Medicaid beneficiaries, out-of-pocket costs are nominal, generally ranging from $0 to $10 per treatment session.
Regional Pricing & Out-of-Pocket Breakdown by State
While WAC drug prices are uniform nationwide, total billing varies significantly across regional markets. Differences in commercial insurance reimbursement rates, local cost of living, clinical staffing costs, and facility types (academic medical centers vs. private outpatient clinics) create regional pricing tiers.
| Region & Representative States | Average Uninsured Cash Price (Per 84 mg Session) | Commercial Insured Out-of-Pocket (Per Session)* | Medicare Part B Coinsurance (No Medigap) | Medicaid Typical Out-of-Pocket |
|---|---|---|---|---|
| Northeast (NY, MA, NJ, PA) | $950 – $1,600 | $10 – $150 | $170 – $240 | $0 – $3.90 |
| West / Pacific (CA, WA, OR, AK) | $900 – $1,550 | $10 – $175 | $165 – $235 | $0 – $5.00 |
| Midwest (IL, OH, MI, MN) | $750 – $1,250 | $10 – $120 | $145 – $200 | $0 – $4.00 |
| South / Southeast (FL, TX, GA, NC) | $700 – $1,200 | $10 – $125 | $140 – $195 | $0 – $3.00 |
| Mountain West & Plains (CO, AZ, UT, KS) | $725 – $1,300 | $10 – $130 | $145 – $205 | $0 – $4.00 |
*Reflects out-of-pocket cost after applying manufacturer copay savings assistance programs for eligible commercial plans.
Key Factors That Influence Total Patient Cost
- Delivery Model (Buy-and-Bill vs. Specialty Pharmacy):
- Buy-and-Bill: The clinic purchases Spravato directly, administers it, and bills the patient’s medical insurance (G2082/G2083). This often streamlines billing into a single medical claim.
- Specialty Pharmacy / Assignment of Benefits: The drug is ordered per-patient from a specialty pharmacy (billed under pharmacy benefits), while the clinic bills separately for the 2-hour observation service. This can lead to separate copays for the drug and the office visit.
- Facility Setting: Hospital outpatient departments (HOPDs) frequently attach facility fees to the observation period, increasing total billed costs compared to independent community psychiatric clinics.
- Deductible Timing: Patients starting treatment early in the calendar year who have not met their annual health plan deductible will face higher initial out-of-pocket expenses until the deductible is satisfied.
- Dosage Requirements: The 84 mg maintenance dosage requires three devices, which carries a higher WAC and higher corresponding HCPCS billing rate (G2083) than the 56 mg induction dose (G2082).
How to Find Affordable Care for Spravato Treatment
Navigating Spravato financial assistance requires strategic coordination between the patient, the clinic’s billing department, and manufacturer support services.
+-----------------------------------------------------------------------+
| Financial Assistance Options |
+-----------------------------------------------------------------------+
| Commercial Patients -----> SPRAVATO withMe Savings Program |
| ($10 copay/session; up to $8,150/yr cap) |
| |
| Uninsured / Low Income --> Johnson & Johnson Patient Assistance |
| Foundation (JJPAF) (Free drug for standard|
| qualifying criteria) |
| |
| Government Insured ------> Non-profit Foundation Grants |
| (PAN Foundation, Good Days, HealthWell) |
+-----------------------------------------------------------------------+
Actionable Steps for Patients
- Enroll in SPRAVATO withMe: Eligible commercially insured patients should immediately enroll in the manufacturer copay program (SPRAVATO withMe). This program can lower out-of-pocket medication copays to as low as $10 per session, subject to an annual maximum benefit (typically up to $8,150 per calendar year).
- Explore the Observation Rebate: In addition to drug copay support, manufacturer programs offer observation rebates to help offset out-of-pocket costs associated with the 2-hour clinical monitoring fee.
- Apply for Patient Assistance (Uninsured): Uninsured patients or those meeting low-income threshold requirements can apply for the Johnson & Johnson Patient Assistance Foundation (JJPAF), which provides Spravato at zero cost for qualifying individuals.
- Verify In-Network Status: Confirm that both the rendering provider and the facility are in-network with your insurer to avoid non-covered out-of-network balance billing.
Best Practices for Clinic Owners and Billing Staff
- Conduct Benefit Investigations (BI) First: Prior to initiating the first dose, complete a thorough BI to verify whether the patient’s plan prefers medical (buy-and-bill) or pharmacy benefit processing.
- Establish Clear Self-Pay Bundles: For self-pay patients who do not qualify for assistance, establish transparent, bundled self-pay packages (combining medication and monitoring into a single flat fee) to provide financial predictability.
- Streamline Prior Authorization Workflows: Maintain standardized documentation verifying TRD diagnosis, past oral antidepressant trial failures (with dates and dosages), and baseline depression rating scale scores (e.g., PHQ-9 or MADRS) to minimize PA delays and claim denials.